26447-74-5

Usage

Uses

Used in Pharmaceutical Synthesis:
2-CHLORO-N-(5,6-DIMETHYL-BENZOTHIAZOL-2-YL)-ACETAMIDE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic benefits.
Used in Agrochemical Production:
In the agrochemical industry, 2-CHLORO-N-(5,6-DIMETHYL-BENZOTHIAZOL-2-YL)-ACETAMIDE is utilized as an intermediate in the creation of compounds designed to protect crops and enhance agricultural productivity.
Used in Neurological Disorder Treatment:
2-CHLORO-N-(5,6-DIMETHYL-BENZOTHIAZOL-2-YL)-ACETAMIDE is studied for its potential applications in the treatment of neurological disorders, given its capacity to interact with biological systems relevant to such conditions.
Used in Antimicrobial Applications:
2-CHLORO-N-(5,6-DIMETHYL-BENZOTHIAZOL-2-YL)-ACETAMIDE is employed for its antimicrobial properties, serving as a component in products designed to combat microbial infections.
Used in Antifungal Applications:
2-CHLORO-N-(5,6-DIMETHYL-BENZOTHIAZOL-2-YL)-ACETAMIDE is used in antifungal applications due to its ability to inhibit fungal growth, making it valuable in various medical and industrial settings where fungal control is necessary.

Upstream product

• 29927-08-0 2-amino-5,6-dimethylbenzothiazole 
• 79-04-9 chloroacetyl chloride 

Relevant academic research and scientific papers

Mechanistic insights into binding of ligands with thiazolidinedione warhead to human histone deacetylase 4

Recently, we have reported that non-hydroxamate thiazolidinedione (TZD) analogs are capable of inhibiting human deacetylase 4 (HDAC4). This study aims at the dissection of the molecular determinants and kinetics of the molecular recognition of TZD ligands by HDAC4. For this purpose, a structure activity relationship analysis of 225 analogs was combined with a comprehensive study of the enzyme and binding kinetics of a variety of HDAC4 mutant variants. The experimental data were rationalized by docking to the two major conformations of HDAC4. TZD ligands are competitive inhibitors and bind via a two-step mechanism involving principal molecular recognition and induced fit. The residence time of 24 g is (34 ± 3) min and thus much larger than that of the canonical pan-HDAC inhibitor SAHA ((5 ± 2) min). Importantly, the binding kinetics can be tuned by varying the structure of the CAP group.

Fighting against alzheimer’s disease: Synthesis of new pyrazoline and benzothiazole derivatives as new acetylcholinesterase and MAO inhibitors

Background: Alzheimer’s Disease (AD) is a complicated neurodegenerative disorder with a multifaceted pathogenesis.AD, characterized by gradual memory loss, falling in language ability and other cognitive deterioration, and has been a prominent risk to ageing population. This means that there is an urgent need to find new lead compounds for controlling and fighting against (AD). In this way, a new thiophene-2-pyrazoline derivatives (A1-A5) and benzothiazole derivatives (A6-A13) have been synthesized to give beneficial compounds to controlling and battling against (AD). Results: Compounds A5 and A13 showed the most remarkable activity with an 18.53 μM and 15.26 μM IC50 values against AChE enzyme. In like manner, compound A4 was active with a 20.34 μM IC50 value against MAO-A. These active compounds are in fact non-toxic making them very attractive for additional future studies. Enzyme kinetic was analyzed and the Lineweaver-Burk plot reveals that compound A13 was typically mixed AChE inhibitors, which showed significant similarity to donepezil. In addition, the best docking pose was done by analyzing the docking pattern of the most active compound A13 which was very compatible with the gorge and in interaction with both CAS and PAS. Conclusion: The synthesis of new thiophene-2-pyrazoline and benzothiazole derivatives targeting AChE/(MAO-A)/(MAO-B) enzymes was described. The selection of enzyme-kinetic analysis, molecular docking and toxicity test was led to good understanding to the therapeutic potential for the active derivatives. Therefore, these compounds may be accepted as promising leads for future research efforts in fighting against AD.

SUBSTITUTED HETEROCYCLIC COMPOUNDS

Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.